Select Page

South Delhi Pharma, New Delhi, India

XOSPATA ® (gilteritinib) tablets, for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

XOSPATA is a prescription medicine.XOSPATA is used to treat acute myeloid leukaemia (AML).
INDICATIONS AND USAGE
XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
DOSAGE FORMS & STRENGTHS
120 mg orally once daily.
Manufactured By: Astellas Pharma US, Inc
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “XOSPATA ® (gilteritinib) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

4 + 2 =

Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.[6] It acts as an inhibitor of AXL receptor tyrosine kinase, hence it is a tyrosine kinase inhibitor.

It was developed by Astellas Pharma.

In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).[8]

In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients.

Gilteritinib was approved for medical use in Australia in March 2020.

2 reviews for XOSPATA ® (gilteritinib) tablets, for oral use.

  1. Submit Link

    Took me time to read all the comments, but I genuinely enjoyed the post. It proved to become Very helpful to me and I am sure to all the commenters right here It is always nice when you can not only be informed, but also entertained Im positive you had fun writing this article.

    http://www.links.m106.com

  2. Facebook Marketing

    I just could not go away your web site prior to suggesting that I actually enjoyed the standard info a person supply to your visitors? Is gonna be back continuously to check out new posts.

    https://www.blogexpander.com/good-solid-advice-about-leadership-that-anyone-can-use/

Add a review

Your email address will not be published.